Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2416 to 2430 of 7710 results

  1. Osimertinib with pemetrexed and platinum-based chemotherapy for untreated EGFR mutation-positive advanced non-small-cell lung cancer [ID6328]

    In development [GID-TA11408] Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. Obicetrapib or obicetrapib–ezetimibe for treating primary heterozygous hypercholesterolaemia or mixed dyslipidaemia [ID6519]

    Awaiting development [GID-TA11649] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Pembrolizumab with lenvatinib and chemotherapy for untreated advanced gastro-oesophageal junction cancer TS ID 11861

    Awaiting development [GID-TA11345] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. NPJ5008 for treating malignant hyperthermia TS ID 11829

      Status ...

    Technology appraisal guidance
    Topic selection

  5. Drug-eluting coronary stents for treating coronary artery disease: late-stage assessment

    In development [GID-HTE10039] Expected publication date: 12 May 2025

    Health technology evaluations
    In development

  6. Amivantamab with carboplatin and pemetrexed for untreated EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer [ID5110]

    In development [GID-TA11023] Expected publication date: 30 April 2025

    Technology appraisal guidance
    In development

  7. Ribociclib with an aromatase inhibitor for adjuvant treatment of hormone receptor-positive, HER2-negative early breast cancer [ID6153]

    In development [GID-TA11090] Expected publication date: 18 June 2025

    Technology appraisal guidance
    In development

  8. One-piece closed bags for colostomies: Late Stage Assessment

    In development [GID-HTE10045] Expected publication date: TBC

    Health technology evaluations
    In development

  9. Osimertinib for maintenance treatment of EGFR mutation-positive locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation [ID6223]

    In development [GID-TA11232] Expected publication date: 20 August 2025

    Technology appraisal guidance
    In development

  10. Teplizumab for delaying the onset of stage 3 type 1 diabetes in people 8 years and over with stage 2 type 1 diabetes [ID6259]

    In development [GID-TA10981] Expected publication date: 16 July 2025

    Technology appraisal guidance
    In development

  11. Givinostat for treating Duchenne muscular dystrophy in people 6 years and over [ID6323]

    In development [GID-TA11373] Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Marstacimab for treating severe haemophilia A or severe haemophilia B in people 12 years and over [ID6342]

    In development [GID-TA11397] Expected publication date: 26 February 2025

    Technology appraisal guidance
    In development

  13. Durvalumab with etoposide and platinum-based chemotherapy for untreated extensive-stage small-cell lung cancer [ID6404]

    Awaiting development [GID-TA11515] Expected publication date: 19 February 2025

    Technology appraisal guidance
    Awaiting development

  14. Bifikafusp alfa–onfekafusp alfa for neoadjuvant treatment of 3B or 3C resectable melanoma [ID6384]

    Awaiting development [GID-TA11458] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Human normal immunoglobulin for preventing infection in chronic lymphocytic leukaemia TS ID 12043

      Status ...

    Technology appraisal guidance
    Topic selection